Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06179043 · ClinicalTrials.gov registry record · NA
Impact of Front-of-package Warning Labels on Perceived Weight Stigmatization
A NA study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- NA
- Development phase
- 2,522
- Enrollment target
NCT06179043: Completed NA study, sponsored by University of North Carolina, Chapel Hill.
NCT06179043 is a NA study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 2,522 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (80% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06179043, a NA study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,522 participants
- Enrollment target
Study Summary
The goal of this experiment is to examine the effects of three different types of front-of-package warning labels for sugar-sweetened beverages on perceived weight stigmatization, as well as the effect of making such labels more weight-neutral. The main questions this experiment aims to answer are: * Are certain types of front-of-package warning labels perceived as more stigmatizing than others? * Are more weight-neutral versions of front-of-package warning labels perceived as less stigmatizing than their regular versions? * Is there a trade-off between label effectiveness in discouraging product consumption and perceived weight stigmatization? Additionally, this experiment also aims to answer the following questions: * Does exposure to certain types of front-of-package warning labels lead to changes in participants' weight bias? * Are changes in participants' weight bias as a result of label exposure mediated by attribution of personal responsibility for body weight, pathogen disgust, or perceived social consensus?
Primary Outcome
Stigmatization of people with obesity will be measured by survey through a three-item scale. Items will inquire about how much participants perceive the label to (1) stigmatize people with obesity, (2) promote negative stereotypes about people with obesity, and (3) portray people with obesity in a disrespectful manner. Response options will be on a 1 to 5 scale, with higher scores representing a higher perceived weight stigmatization by the study labels. Each participant's responses to each item
Interventions
- BEHAVIORAL Nutrient warning labels
- BEHAVIORAL Text-only health warning labels
- BEHAVIORAL Graphic health warning labels
- BEHAVIORAL Control labels
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,522 participants |
| Start Date | 2024-01-18 |
| Est. Completion | 2024-01-26 |
| Phase | NA |
What the finished NCT06179043 record still lists
NCT06179043 is an interventional study that assigns participants to a tested intervention. Its 2,522 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (80% higher).
The record links to 0 conditions, and to 4 interventions - of which Nutrient warning labels is the first listed.
NCT06179043 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06179043 about?
NCT06179043 is a clinical study titled "Impact of Front-of-package Warning Labels on Perceived Weight Stigmatization". The goal of this experiment is to examine the effects of three different types of front-of-package warning labels for sugar-sweetened beverages on perceived weight stigmatization, as well as the effect of making such labels more weight-neutral. The main questions this experiment aims to answer are: ...
What is the current status of trial NCT06179043?
This trial is currently completed. It is a NA study. The enrollment target is 2,522 participants. The study started on 2024-01-18. Estimated completion is 2024-01-26.
What interventions are being tested in trial NCT06179043?
The interventions under investigation include: Nutrient warning labels (BEHAVIORAL), Text-only health warning labels (BEHAVIORAL), Graphic health warning labels (BEHAVIORAL), Control labels (BEHAVIORAL).
Who is sponsoring clinical trial NCT06179043?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06179043's enrollment target sits among peer trials
2,522 44th of 2000 higher than 1,957 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04142177 · 2,529 participants · NA
Sequential and Comparative Evaluation of Pain Treatment Effectiveness Response
- NCT00018057 · 2,530 participants · Phase 2
Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
- NCT05931276 · 2,540 participants · Phase 3
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
- NCT00001160 · 2,500 participants
Studies on Tumors of the Thyroid
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI